| |
|
 John T. Curnutte, MD, PhD
CEO
John T. Curnutte, MD, PhD, joined 3-V Biosciences in May, 2008. Dr. Curnutte has 15 years of experience in the biotechnology/pharmaceutical industry, with focus on inflammation research and infectious diseases clinical experience. As President of Schering-Plough Biopharma (formerly DNAX Research Institute) (2000-2008) he led the drug discovery and early development efforts for biologic therapeutics. From 1993-2000, as Sr. Director in Discovery Research at Genentech, he was responsible for leading the research efforts in the departments of Immunology, Pathology, and Antibody Technology. Prior to Genentech, Dr. Curnutte was a tenured faculty member of The Scripps Research Institute, pursuing basic and clinical research in inflammation biochemistry and the molecular genetics of congenital immune deficiencies. Dr. Curnutte was involved in research and development of Actimmune®, Raptiva®, Rituxan®, Herceptin®, and Xolair®, and 8 additional molecules at DNAX advanced to clinical trials.
Dr. Curnutte received his BA, MD, and PhD degrees from Harvard University. He did his postdoctoral training in pediatrics (Massachusetts General Hospital) and pediatric hematology/oncology (Boston Children’s Hospital and the Dana-Farber Cancer Institute). He is currently an Adjunct Clinical Professor of Pediatrics at the Stanford University School of Medicine and a member of the medical staff, where he continues to consult on patients with primary immunodeficiencies. |
|
